NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis $3.16 +0.03 (+0.96%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.05 -0.11 (-3.35%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Voyager Therapeutics Stock (NASDAQ:VYGR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Voyager Therapeutics alerts:Sign Up Key Stats Today's Range$3.07▼$3.2050-Day Range$2.85▼$4.4252-Week Range$2.75▼$9.55Volume338,684 shsAverage Volume452,871 shsMarket Capitalization$174.45 millionP/E Ratio4.45Dividend YieldN/APrice Target$13.97Consensus RatingBuy Company OverviewVoyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Read More… Voyager Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreVYGR MarketRank™: Voyager Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 86th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingVoyager Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVoyager Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Voyager Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Voyager Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is 4.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is 4.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.94.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Voyager Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.62% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 4.27%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.97 Percentage of Shares Shorted5.62% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 4.27%, indicating that investor sentiment is decreasing. News and Social Media1.5 / 5News Sentiment-0.29 News SentimentVoyager Therapeutics has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Voyager Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,336.00 in company stock.Percentage Held by InsidersOnly 4.53% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Voyager Therapeutics' insider trading history. Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VYGR Stock News HeadlinesAlfred Sandrock Sells 10,885 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) StockApril 6, 2025 | insidertrades.comResearch Analysts Offer Predictions for VYGR FY2026 EarningsApril 20 at 2:35 AM | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 21, 2025 | Porter & Company (Ad)7 Analysts Assess Voyager Therapeutics: What You Need To KnowApril 10, 2025 | nasdaq.comVoyager updates on Alzheimer’s programs ‘compelling,’ says H.C. WainwrightApril 9, 2025 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Voyager Therapeutics (VYGR)April 8, 2025 | markets.businessinsider.com2VYGR : 7 Analysts Assess Voyager Therapeutics: What You Need To KnowApril 8, 2025 | benzinga.comVoyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025April 2, 2025 | nasdaq.comSee More Headlines VYGR Stock Analysis - Frequently Asked Questions How have VYGR shares performed this year? Voyager Therapeutics' stock was trading at $5.67 at the start of the year. Since then, VYGR stock has decreased by 44.3% and is now trading at $3.16. View the best growth stocks for 2025 here. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings data on Tuesday, March, 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.24. The company earned $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a trailing twelve-month return on equity of 8.33% and a net margin of 15.80%. Read the conference call transcript. Who are Voyager Therapeutics' major shareholders? Top institutional shareholders of Voyager Therapeutics include Rhumbline Advisers (0.12%). Insiders that own company stock include Neurocrine Biosciences Inc, Rock Ventures Iii LP Third, Ecor1 Capital, Llc, Robin Swartz, Robert W Hesslein, Todd Alfred Carter, Sandell Jacquelyn Fahey and Glenn Pierce. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings3/11/2025Today4/20/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VYGR CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$13.97 High Stock Price Target$30.00 Low Stock Price Target$5.73 Potential Upside/Downside+342.0%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E Ratio4.45 Forward P/E RatioN/A P/E GrowthN/ANet Income$132.33 million Net Margins15.80% Pretax Margin16.35% Return on Equity8.33% Return on Assets6.15% Debt Debt-to-Equity RatioN/A Current Ratio8.45 Quick Ratio8.45 Sales & Book Value Annual Sales$80.00 million Price / Sales2.18 Cash Flow$2.24 per share Price / Cash Flow1.41 Book Value$5.37 per share Price / Book0.59Miscellaneous Outstanding Shares55,207,000Free Float52,151,000Market Cap$174.45 million OptionableOptionable Beta1.02 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:VYGR) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.